Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study

Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study

Highlights • We compared the outcomes of patients with bacteraemia due to ESBL-producers. • We discuss the implications of ESBL-producers with different flomoxef MICs. • A suboptimal clinical outcome is anticipated when flomoxef is given. • Flomoxef is suggested for bacteraemia due to ESBL-producing...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of antimicrobial agents 2015-12, Vol.46 (6), p.610-615
Hauptverfasser: Lee, Chen-Hsiang, Su, Lin-Hui, Chen, Fang-Ju, Tang, Ya-Feng, Li, Chia-Chin, Chien, Chun-Chih, Liu, Jien-Wei
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Bacteremia - drug therapy
Bacteremia - microbiology
beta-Lactamases - metabolism
Carbapenems - therapeutic use
Case-Control Studies
Case–control study
Cephalosporins - therapeutic use
Cephamycins
Enterobacteriaceae
Escherichia coli - drug effects
Escherichia coli - pathogenicity
Escherichia coli Infections - drug therapy
Escherichia coli Infections - microbiology
Escherichia coli Infections - mortality
Female
Humans
Infectious Disease
Klebsiella Infections - drug therapy
Klebsiella Infections - microbiology
Klebsiella Infections - mortality
Klebsiella pneumoniae - drug effects
Klebsiella pneumoniae - pathogenicity
Male
Microbial Sensitivity Tests
Middle Aged
Mortality
Outcome
Propensity score matching
Retrospective Studies
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • We compared the outcomes of patients with bacteraemia due to ESBL-producers. • We discuss the implications of ESBL-producers with different flomoxef MICs. • A suboptimal clinical outcome is anticipated when flomoxef is given. • Flomoxef is suggested for bacteraemia due to ESBL-producing isolates with a MICflomoxef ≤1 mg/L.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2015.07.020